Format

Send to

Choose Destination
Drug Discov Today Technol. 2014 Mar;11:27-32. doi: 10.1016/j.ddtec.2013.12.004.

Resistance to Raf inhibition in cancer.

Abstract

The use of small molecule BRAF inhibitors has revolutionized the treatment of advanced melanoma. Despite this, resistance is commonplace and associated with a median progression-free survival of >5 months. Major resistance mechanisms include reactivation of the MAPK pathway and increased PI3K/AKT signaling. Here we review some of the combination therapeutic strategies currently undergoing evaluation for the management of acquired drug resistance in melanoma.

PMID:
24847650
PMCID:
PMC4031441
DOI:
10.1016/j.ddtec.2013.12.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center